Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
UCB Biopharma SRL
Age
16–80
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Subjects (male or female) from 16 to 80 years of age at Visit 1, both inclusive
Subjects having at least 8 partial seizures (according to the 1981 ILAE classification) during the 8-Week Baseline Period with at least 2 partial seizures during each 4-week interval of the Baseline Period
Subjects having at least 2 partial seizures whether or not secondary generalization per month during the 3 months preceding Visit 1
Subjects uncontrolled while treated by 1 or 2 permitted concomitant antiepileptic drug \[AED\](s). Vagal Nerve Stimulation (VNS) is allowed and will be counted as a concomitant AED
You may not be if
Subject has history or presence of status epilepticus during the year preceding Visit 1 or during Baseline
Subject is currently treated with levetiracetam
Subject has taken levetiracetam within 90 days prior to Visit 1
Clareo Health | A Study to Evaluate the Efficacy and Safety of Brivaracetam in Study Participants (>=16 to 80 Years of Age) With Epilepsy
